Physician profile
Mark Ramzy
NPI 1841729340
$31,227.36
in general payments reported to CMS, 2019-2025
16 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $94.91 · 2023: $734 · 2024: $18K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $1,697 · Travel and Lodging: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,000.00 |
| Food and Beverage | $1,697.24 |
| Travel and Lodging | $1,435.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verathon INC. | $27,100.00 | 2024-2025 | Video Laryngoscope & Bronchoscope, Bronchoscope |
| Ge Healthcare | $1,500.96 | 2025 | |
| Abbott Laboratories | $910.45 | 2024 | Trifecta, Thoratec Heartmate 3 Lvas Implant Kit |
| Mindray Ds USA, INC. | $467.84 | 2024 | Te X, Te7 Max |
| Astrazeneca Pharmaceuticals Lp | $330.36 | 2022-2023 | Andexxa |
| Alexion Pharmaceuticals, INC. | $125.30 | 2023 | |
| Bioxcel Therapeutics, INC. | $124.61 | 2023 | Igalmi |
| Gilead Sciences, INC. | $121.83 | 2023 | Veklury |
| Shionogi INC | $109.65 | 2024 | Fetroja |
| Csl Behring | $107.70 | 2025 | Kcentra |
| Abiomed | $95.96 | 2024 | Impella |
| Abbvie INC. | $89.90 | 2023 | |
| Baxter Healthcare | $59.02 | 2024 | Preveleak |
| Atricure, INC. | $46.96 | 2024-2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Vapotherm INC | $20.06 | 2023 | Vapotherm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $16.76 | 2023 | Angiovac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ramzy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.